

From: [Trials](#)
To: [Knauss, Daniel](#); [Trials](#)
Cc: [Rhyu, Michelle](#); [Cochran, Andrew](#); [Flattmann Jr., Gerald J.](#)
Subject: RE: PTAB-IPR-2023-01069, -01070; Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc.
Date: Thursday, October 19, 2023 9:50:09 AM

Counsel,

From the Board –

Petitioner is authorized to file reply briefs in IPR2023-01069 and -01070. Petitioner's briefs are limited to discretionary denial issues, shall not exceed six pages, and are due by COB on November 10, 2023. Patent Owner may file responsive sur-replies of no more than six pages. Any such sur-replies are limited to addressing Petitioner's arguments in the replies, and shall be filed by COB on December 1, 2023.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Knauss, Daniel <dknauss@cooley.com>
Sent: Wednesday, October 18, 2023 5:20 PM
To: Trials <Trials@USPTO.GOV>
Cc: Rhyu, Michelle <RHYUMS@cooley.com>; Knauss, Daniel <dknauss@cooley.com>; Cochran, Andrew <ACochran@cahill.com>; Flattmann Jr., Gerald J. <GFlattmann@Cahill.com>
Subject: PTAB-IPR-2023-01069, -01070; Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc.

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc.
IPR2023-01069
IPR2023-01070

Dear Board,

Petitioner in the above-listed cases requests authorization to file a preliminary reply of no more than six pages to address Patent Owner's arguments regarding discretionary denial of institution in its Preliminary Response. Petitioner conferred with Patent Owner and the parties agreed to the following briefing schedule, pending approval by the Board:

- Petitioner to file a reply brief limited to discretionary denial issues of no more than six pages by November 10, 2023.

IPR2023-01069, -01070
Ex. 3001

- Patent Owner to file a surreply brief of equal length to Petitioner's reply, limited to addressing Petitioner's arguments in the reply brief, by December 1, 2023.

Please let us know if the Board desires a conference call to discuss the matter, in which case the parties can promptly provide their availability.

Respectfully submitted,

Dan Knauss (56,393)
Counsel for Petitioner

Daniel J. Knauss, J.D., Ph.D.
Cooley LLP

3175 Hanover St.
Palo Alto, Cal. 94304

Direct: (650) 843-5287 • Mobile: (650) 440-3976 • Fax: (650) 849-7400

Email: dknauss@cooley.com • Bio: www.cooley.com/dknauss
Practice: [Life Sciences IP Litigation](#)

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.